- •Contents
- •Introduction
- •Contributors
- •ROLE OF BIOPSY
- •DIRECTED TREATMENTS OF DISTINCT ORBITAL INFLAMMATIONS
- •ABSTRACT
- •ACKNOWLEDGEMENTS
- •5 Future and Emerging Treatments for Microbial Infections
- •MICROBIOLOGIC DIAGNOSIS
- •EMERGING ANTIBIOTIC RESISTANCE
- •HISTORICAL PERSPECTIVE
- •CURRENT APPROACH
- •FUTURE DIRECTIONS
- •7 Non-Hodgkin’s Lymphoma
- •INCIDENCE AND EPIDEMIOLOGY
- •ETIOLOGY AND RISK FACTORS
- •DIAGNOSIS, CLASSIFICATION, AND STAGING
- •TREATMENT
- •ABSTRACT
- •INTRODUCTION
- •STEPS TOWARD TUMOR SPECIFIC THERAPY
- •CANCER SPECIFIC MOLECULAR TARGETS
- •DNA ARRAY ANALYSIS
- •WHICH MOLECULAR TARGETS?
- •CONCLUSIONS
- •10 Malignant Lacrimal Gland Tumors
- •THERAPEUTIC RECOMMENDATIONS
- •SPHENOID WING MENINGIOMAS
- •Location
- •PRESENTING SIGNS AND SYMPTOMS
- •RADIOGRAPHIC IMAGING
- •ULTRASOUND
- •HISTOPATHOLOGY
- •TREATMENT AND PROGNOSIS
- •13 Stereotactic Radiotherapy for Optic Nerve and Meningeal Lesions
- •BACKGROUND
- •DEFINITIONS
- •Precise Immobilization
- •Precise Tumor Localization
- •Conformal Treatment Planning and Delivery
- •FUTURE DEVELOPMENTS
- •SUMMARY
- •ABSTRACT
- •INTRODUCTION
- •ABSTRACT
- •INTRODUCTION
- •Enzyme-Linked Immunosorbent Assay (ELISA)
- •Prospective Study of Graves’ Disease Patients
- •DISCUSSION
- •ACKNOWLEDGEMENTS
- •ORBITAL FIBROBLASTS DISPLAY CELL-SURFACE CD40 AND RESPOND TO CD154
- •CONCLUSIONS
- •ACKNOWLEDGEMENTS
- •INTRODUCTION
- •Retina, RPE, and Choroid
- •Optic Nerve
- •ACKNOWLEDGMENT
- •INTRODUCTION
- •METHODS
- •Historical Features
- •Tempo of Disease Onset
- •Clinical Features
- •DISCUSSION
- •19 Prognostic Factors
- •PREVENTION OF GRAVES’ OPHTHALMOPATHY BY EARLIER DIAGNOSIS AND TREATMENT OF GRAVES’ HYPERTHYROIDISM?
- •CLINICAL ACTIVITY SCORE
- •ORBITAL ECHOGRAPHY
- •ORBITAL OCTREOSCAN
- •ORBITAL MAGNETIC RESONANCE IMAGING
- •URINARY GLYCOSAMINOGLYCANS
- •SERUM CYTOKINES
- •CONCLUSION
- •BACKGROUND
- •VISA CLASSIFICATION
- •Strabismus
- •Appearance=Exposure
- •DISCUSSION
- •INTRODUCTION
- •NONSEVERE GRAVES’ OPHTHALMOPATHY
- •SEVERE GRAVES’ OPHTHALMOPATHY
- •Glucocorticoids
- •Orbital Radiotherapy
- •Immunosuppressive Drugs
- •Plasmapheresis
- •Somatostatin Analogues
- •Intravenous Immunoglobulins
- •Antioxidants
- •Cytokine Antagonists
- •Colchicine
- •INTRODUCTION
- •STABLE ORBITOPATHY
- •Preferred Decompression Techniques
- •EYE MUSCLE SURGERY
- •LID PROCEDURES
- •PATHOPHYSIOLOGY OF THE DISEASE
- •MEDICAL THERAPY
- •IMPROVEMENTS IN ORBITAL DECOMPRESSION
- •IMPROVEMENTS IN EYELID SURGERY
- •STRABISMUS SURGERY
- •Michael Kazim
- •John Kennerdell
- •Daphne Khoo
- •Claudio Marcocci
- •Jack Rootman
- •Wilmar Wiersinga
- •Answer
- •Question 1 (continued)
- •Answer
- •Question 2 (from M. Potts)
- •Answer
- •Question 2 (continued)
- •Question 3
- •Answer
- •Question 3 (continued)
- •Answer
- •Question 3 (continued)
- •Answer
- •Question 3 (continued)
- •Answer
- •Question 4 (from M. Mourits)
- •Answer
- •Question 5 (from F. Buffam)
- •Answer
- •Question 6 (from F. Buffam)
- •Answer
- •Question 7 (from P. Dolman)
- •Answer
- •INTRODUCTION
- •CLINICAL MANIFESTATIONS OF DVVMs
- •INVESTIGATION OF DVVMs
- •FUTURE CONSIDERATIONS
- •CONCLUSION
- •INTRODUCTION
- •CAROTID-CAVERNOUS SINUS FISTULAS
- •ARTERIOVENOUS MALFORMATIONS
- •DISTENSIBLE VENOUS ANOMALIES
- •PREOPERATIVE EMBOLIZATION OF TUMORS
- •ANEURYSMS
- •FUTURE DIRECTIONS
- •ABSTRACT
- •INTRODUCTION
- •TECHNOLOGICAL ADVANCEMENTS
- •Advances in Medical Imaging
- •Virtual Reality Surgical Simulation
- •Surgical Robotics
- •HUMAN BODY MODELS
- •FUTURE COMPUTER-AIDED ORBITAL SURGERY
- •SUMMARY
- •ACKNOWLEDGMENTS
- •30 The Future of Orbital Surgery
- •Index
18
Predictors of Disease Severity in
Thyroid-Related Orbitopathy
PETER J. DOLMAN and |
JUGPAL ARNEJA |
JACK ROOTMAN |
The Faculty of Medicine, |
|
|
Department of Ophthalmology and |
University of Manitoba, Winnipeg, |
Visual Sciences and Department of |
Manitoba, Canada |
Pathology, University of British |
|
Columbia and the Vancouver General |
|
Hospital, Vancouver, |
|
British Columbia, Canada |
|
INTRODUCTION
Most patients suffering from thyroid orbitopathy (TO) develop mild disease with lid retraction and proptosis; however, a minority may have a more aggressive presentation with greater inflammatory features, progressive restriction of ocular motility, and possible optic neuropathy (1–3).
To date, there are only a few known prognostic variables concerning disease severity, with smoking, male gender, and
203
204 |
Dolman et al. |
age increasing the likelihood of progression to a severe level requiring aggressive therapy (4,5).
This study compared retrospectively the demographic, historic, and clinical variables on first presentation and on the consecutive visit in 50 patients with mild and 50 patients with severe disease to determine possible prognosticators of severity in TO.
METHODS
This was a retrospective case–control study using chart review. The charts from 340 new patients consecutively referred to the University of British Columbia Thyroid Orbitopathy Clinic between 1993 and 1996 were separated into two groups based on therapy during the active phase of their disease. At our clinic, we grade the inflammatory activity of thyroid orbitopathy using a clinical activity index similar to that described by Mourits et al. (Table 1). We categorize patients with inflammatory scores less than 4 (out of a possible 8), with no progressive strabismus, and without optic neuropathy, as having mild disease and treat them conservatively with observation, lubricant eye drops, or cool compresses. We define severe disease as including those patients with an inflammatory score of 4 or greater out of 8, with progressive ocular motility restriction, or with optic neuropathy. These patients are offered more aggressive
Table 1 Thyroid Orbitopathy Inflammatory Score
(UBC Thyroid Orbitopathy Clinic)
Clinical finding |
Score |
|
|
Orbital pain (none, at rest, movement) |
0–2 |
Chemosis |
0–2 |
Eyelid edema |
0–2 |
Conjunctival injection |
0–1 |
Eyelid injection |
0–1 |
Total |
0–8 |
|
|
Predictors of Disease Severity |
205 |
therapy including systemic anti-inflammatories and=or orbital radiation.
From each of the two groups, 50 patients were randomly selected using a computer-generated sequence and their charts reviewed for differences in symptoms, signs, rate of disease onset, and progression between their first and subsequent visit. Statistical analysis was applied using Student’s t-test, w2-test, and Mann–Whitney U-test.
RESULTS
Demographics
Of the 340 patients initially reviewed, we classified 119 (35%) as having severe disease and 221 (65%) with mild disease. The randomly selected groups of 50 patients each were compared for age, sex, race, family history, and smoking history (Table 2).
The mean age at presentation of patients in the severe group was 55.4 years and in the mild group 39.3 years; this difference was statistically significant (p < 0.0001, Student’s t-test).
The severe group included 73.8% females and 26.2% males, while the mild group had 83% females and 17% males;
Table 2 Demographic Comparison Between Disease Severity Groups (Student’s t- and w2-tests)
Category |
Severe disease |
Mild disease |
p Value |
||
|
|
|
|
|
|
Age (years) |
|
|
|
|
|
Mean |
55.4 |
|
39.3 |
|
p < 0.00001 |
Standard deviation |
12.2 |
|
11.8 |
|
|
Gender |
73.8% |
F |
83.0% |
F |
p > 0.05 |
|
26.2% |
M |
17.0% |
M |
|
Race |
90.5% white |
66.0% white |
p < 0.006 |
||
|
9.5% other |
34.0% other |
|
||
Smokers |
57.1% |
|
44.7% |
|
p > 0.05 |
Family history |
33.3% |
|
27.7% |
|
p > 0.05 |
|
|
|
|
|
|
206 |
|
|
Dolman et al. |
these |
gender distributions |
were statistically |
insignificant |
(p > 0.05). |
|
|
|
A |
significant difference |
(p < 0.006) was |
present with |
regard to racial distribution, with the severe group comprised of 90.5% white and 9.5% other races (Chinese, Indian, Native American Indian, and African) and the mild group comprised of 66% white and 34% others.
A positive smoking history was present in 57.1% of the severe group and 44.7% of the mild group, which was found to be not statistically different (p > 0.05).
A positive family history of thyroid orbitopathy was present in 33.3% of the severe group and 27.7% of the mild group, statistically not different (p > 0.05).
Historical Features
Symptoms of thyroid orbitopathy and systemic thyroid disease were recorded at the initial presentation (Table 3).
Diplopia and lid and conjunctival swelling were reported more frequently in the severe group than in the mild group and found to have a statistically significant difference (p < 0.0005). Orbital pain (including both deep orbital aching as well as foreign body irritation) was reported equally commonly in both groups (p > 0.05).
Table 3 Comparison of Symptoms Between Disease Severity
Groups (w2-test)
Symptom |
Severe disease (%) |
Mild disease (%) |
p Value |
|
|
|
|
Orbit symptoms |
|
|
|
Diplopia |
59.5 |
19.1 |
p < 0.0001 |
Lid swelling |
85.7 |
38.2 |
p < 0.00001 |
Orbit pain |
61.9 |
53.2 |
p > 0.05 |
Proptosis |
52.4 |
87.2 |
p < 0.0004 |
Thyroid symptoms |
|
|
|
Weight change |
69.0 |
70.2 |
p > 0.05 |
Palpitations |
33.3 |
38.3 |
p > 0.05 |
Heat intolerance |
21.4 |
51.1 |
p < 0.004 |
|
|
|
|
